Advertisement

Child's Nervous System

, Volume 35, Issue 11, pp 2033–2034 | Cite as

Monitoring of biochemical parameters and coagulation tests in children with epilepsy treated with levetiracetam monotherapy

  • Achilleas AttilakosEmail author
  • Argirios Dinopoulos
  • Maria Paschalidou
  • Maria Tsirouda
  • Anastasia Garoufi
Letter to the Editor
  • 71 Downloads

Dear Editor:

Levetiracetam (LEV)-associated hyponatremia, hypokalemia, and hypomagnesemia and increase in serum albumin have been described in adult patients [2, 5, 7]. Furthermore, in well-controlled studies of add-on levetiracetam therapy for epilepsy, the incidence of coagulation and bleeding disorders was slightly higher in the LEV group than that in the placebo group (2.8% vs 1.7%) [3]. Whether young age may have a protective role in the prevention of the above LEV-associated disorders has not been studied. The objective of this study was to prospectively investigate the long-term effect of LEV monotherapy in all the above parameters in children with epilepsy.

The study population consisted of 28 ambulatory children (16 females, mean age 6.5 ± 4.4 years, range 1–15 years) that were treated for new-onset epilepsy with LEV monotherapy. Twenty-three children suffered from focal epilepsy and 5 from generalized epilepsy. An informed parental consent was obtained and the study was...

Notes

Compliance with ethical standards

An informed parental consent was obtained and the study was approved by the Institutional Review Board of “Attikon” University Hospital.

Conflict of interest

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

References

  1. 1.
    Baier H, Bosiger J, Bombeli T, Kramer G (2003) Levetiracetam might induce or aggravated von Willebrand disease: a case report [abstract]. Epilepsia 44(suppl 8):118Google Scholar
  2. 2.
    Belcastro V, Costa C, Striano P (2008) Levetiracetam-associated hyponatremia. Seizure 17:389–390CrossRefGoogle Scholar
  3. 3.
    Boon P, Hulhoven R, Offner F (2007) Levetiracetam and bleeding disorders. Acta Neurol Belg 107:97–102PubMedGoogle Scholar
  4. 4.
    Eccher M, Swartz BE, Werz MA, Robinson S, Maciunas RJ (2002) Possible relation of levetiracetam therapy to hemorrhagic complications in epilepsy surgery [abstract]. Epilepsia 43(suppl 7):206Google Scholar
  5. 5.
    Morimoto M, Hashimoto T, Kitaoka T, Kyotani S (2018) Impact of oxidative stress and newer antiepileptic drugs on the albumin and cortisol value in severe motor and intellectual disabilities with epilepsy. J Clin Med Res 10:137–145CrossRefGoogle Scholar
  6. 6.
    Rosca EC, Simu M (2017) Levetiracetam-induced hyponatremia. Acta Neurol Belg 118:123–124CrossRefGoogle Scholar
  7. 7.
    Vallianou NG, Geladari E, Chroni P, Kokkinakis E (2015) Levetiracetam-associated hypokalemia and hypomagnesaemia among two patients treated for seizures. CNS Neurosci Ther 21:539CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Third Department of Pediatrics, National and Kapodistrian University of Athens“Attikon” HospitalAthensGreece
  2. 2.Second Department of Pediatrics, National and Kapodistrian University of Athens“P&A Kyriakou” Children’s HospitalAthensGreece

Personalised recommendations